2 weeks Ago By Defense World Staff
Wells Fargo & Company MN boosted its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 35.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).
The fund owned 61,255 shares of the medical device company’s stock after purchasing an additional 16,163 shares during the period. Wells Fargo & Company MN owned about 0.09% of Tandem Diabetes Care worth $2,206,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. AlphaQuest LLC lifted its holdings in shares of Tandem Diabetes Care by 138.7% during the fourth quarter.
AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after purchasing an additional 541 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of Tandem Diabetes Care by 195.8% in the fourth quarter.
Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock worth $41,000 after acquiring an additional 748 shares during the period. Assetmark Inc. boosted its holdings in Tandem Diabetes Care by 77.
5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 535 shares during the last quarter.
McIlrath & Eck LLC acquired a new stake in Tandem Diabetes Care during the 3rd quarter valued at approximately $52,000. Finally, Smartleaf Asset Management LLC raised its holdings in Tandem Diabetes Care by 163.4% during the 4th quarter.
Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock worth $65,000 after purchasing an additional 1,101 shares during the last quarter. Insider ActivityIn related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average cost of $18.
12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now owns 10,538 shares of the company’s stock, valued at $190,948.
56. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Corporate insiders own 2.20% of the company’s stock. Tandem Diabetes Care Price PerformanceTNDM stock opened at $18.
06 on Friday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.
32 and a current ratio of 2.90. The business has a 50-day simple moving average of $20.
17 and a two-hundred day simple moving average of $29.29. The company has a market capitalization of $1.
20 billion, a P/E ratio of -9.36 and a beta of 1.52.
Tandem Diabetes Care, Inc. has a 52-week low of $15.75 and a 52-week high of $53.
69. Wall Street Analysts Forecast GrowthSeveral research firms have recently weighed in on TNDM. Royal Bank of Canada decreased their price objective on shares of Tandem Diabetes Care from $65.
00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. The Goldman Sachs Group dropped their price objective on Tandem Diabetes Care from $42.
00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Morgan Stanley cut Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $45.
00 to $22.00 in a research note on Wednesday, March 5th. Canaccord Genuity Group reissued a “buy” rating and issued a $63.
00 price target on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $22.00 price objective (down previously from $38.
00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $43.
81.Check Out Our Latest Stock Analysis on Tandem Diabetes CareTandem Diabetes Care Profile (Free Report)Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Further ReadingFive stocks we like better than Tandem Diabetes CareStock Average Calculator Short Sellers Gave Up on These 3 Names RecentlyWhat Are the U.K. Market Holidays? How to Invest and Trade3 Boring Stocks Outperforming the Market This YearWhat is the Euro STOXX 50 Index?If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyWant to see what other hedge funds are holding TNDM? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report)..
